Cargando…
lloprost delivered via the BREELIB(TM) nebulizer: a review of the clinical evidence for efficacy and safety
Inhaled iloprost is a well-established medication to treat pulmonary arterial hypertension (PAH), a serious and potentially fatal disease of the pulmonary resistance vessels. The therapeutic administration of iloprost requires six to nine inhalations per day, due to the short biological half-life of...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421612/ https://www.ncbi.nlm.nih.gov/pubmed/30874487 http://dx.doi.org/10.1177/1753466619835497 |